MAPT and Alzheimer disease: There is a growing consensus that aggregation-prone amyloid-β (Aβ) and tau proteins are associated with AD pathologies (2), which need to be therapeutically targeted before symptoms become visible in individuals such as memory loss, impulsive behavior, loss of spontaneity, increased anxiety, and confusion.